|Bid||65.90 x 1400|
|Ask||65.91 x 1400|
|Day's Range||65.57 - 66.23|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||14.54|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||2.52 (3.87%)|
|1y Target Est||80.51|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...
O’Day faced questioning at a Thursday hearing over the high price of Truvada, a medicine approved to treat HIV and prevent infection. Activists claim that the price prevents at-risk people from accessing the drug and has helped keep infection rates high. Truvada’s annual list price has nearly tripled in the U.S. to more than $20,000 over the past 15 years. News broke in April that the government is reviewing patents on Truvada’s preventative use that could entitle taxpayers to millions in royalties.
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Gilead Sciences (GILD) is a major biopharmaceuticals producer focusing on life-threatening diseases. Founded in 1987 by Michael Riordan, a 29-year-old medical doctor, Gilead has grown to over $22 billion in revenues, notes George Putnam, editor of The Turnaround Letter.
The Gilead CFO is using her career and platform to enable the next generation to come up and succeed.
-- New Safety Data Involving Steroid Use and New Subpopulation Analyses from Pivotal ZUMA-1 Trial to Provide Greater Understanding of Yescarta® in Patients with Relapsed or Refract
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
Buy Services, Sell Goods, Says Goldman Sachs If Tariff War Explodes The people at Goldman Sachs (NYSE:GS) may know a bit about trading, or maybe not, but either way, they’re saying to sell goods stocks and buy services stocks if the Chinese retaliate to the Trump Administration’s latest move to jack up tariffs on $200 […]The post Market Morning: Kudlow Cracks, Brexiters Rage, Gilead Butters Up FDA, Philip Morris Backtracks appeared first on Market Exclusive.
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
Gilead will donate its PrEP medication Truvada, which is used to reduce the risk of HIV infection and usually sells for $1,600 to $2,000 a month in the United States.
The Health and Human Services Department announced Thursday that California-based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.
WASHINGTON (AP) — The Health and Human Services Department announced Thursday that California-Based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
Gilead Sciences, Inc. (GILD) today announced that it will donate Truvada for PrEP® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV and end the epidemic. This medication donation is among the largest ever in the United States and is part of Gilead’s broader ongoing initiatives to help ensure that everyone who can benefit from PrEP is able to access it. Gilead will provide to CDC up to 2.4 million bottles of Truvada® annually for uninsured Americans at risk for HIV.
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.